carotid artery stenosis
Conditions
Interventions
RASI group : Take RASI, with or without other antihypertensive drugs except for CCB
and blood pressure should be controlled within the target range(140/90 mmHg).
CCB group : Take CCB, with or without other antihypertensive drugs except for RASI
and blood pressure should be controlled within the target range(140/90 mmHg)
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1.age = 18 2.with a TIA or nondisabling ischemic stroke within the past 6 months and ipsilateral moderate-severe (50%–99%) extracranial carotid artery stenosis or with severe extracranial carotid artery stenosis (70%-90%); and the cause of stenosis was atherosclerosis. Diagnosed by digital subtraction DSA, CTA, MRA or ultrasonic imaging. 3.with hypertension requiring hypertensives 4.peri-operation modified Rankin scale < 3 5. with written consent from participants
Exclusion criteria
Exclusion criteria: 1. with ipsilateral tandem stenosis 2.with history of operation in contralateral carotid artery, like stenting, endarterectomy and bypass. 3.requiring operation in contralateral carotid artery in the same admission. 4. requiring general anesthesia in the same operation (stenting) 5.with contraindication to carotid stenting, such as Inability to tolerate surgery due to organ dysfunction, cerebral aneurism, cerebral hemorrhage in 3 months, myocardial infraction or large-area cerebral infraction within 2 weeks, extreme tortuosity of the vessel 6.allergic to Calcium channel blockers, angiotensin receptor blockers or hydrochlorothiazide 7. Pregnancy 8. with concomitant medication as following: Azole antifungals, macrolides antibiotics, cardiac calcium channel blockers, Rifampicin, sildenafil, simvastatin, immunosuppressants, antidepressants, valproic acid, cimetidine, aliskiren, NSAIDs, protease inhibitors (ritonavir) and drugs that affect potassium in the blood. 9.with hepatic insufficiency, renal insufficiency, kidney transplantation, diabetic nephropathy, biliary obstructive disease, or the presence of end-stage disease affecting clinical prognosis assessment (end-stage cancer, end-stage heart disease, liver failure, renal failure, pulmonary failure, etc) 10. with depression, schizophrenia, bipolar disorder, epilepsy, tuberculosis, AIDS, primary hyperaldosteronism, hyperkalemia, hypercalcemia, hyperuricemia, gout 11. participating other trails which would affect the evaluation of outcomes 12. with reserpine and clonidine intake within 1 week
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of persistent hypotension after operation; | — |
Secondary
| Measure | Time frame |
|---|---|
| Postoperative hospital stay;Postoperative hospitalization costs;Changes in plasma concentrations of catecholamines before and after surgery;Changes in autonomic nerve function before and after surgery; of postoperative bradycardia;Incidence of postoperative hypotension; | — |
Countries
China
Contacts
Public ContactBo Wu
West China Hospital of Sichuan University
Outcome results
None listed